Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP08732695A	2020-12-11	Galenicum Health S.L.U.	Granted and Under Opposition
EP08732695A	2020-12-11	Generics [UK] Limited	Granted and Under Opposition
EP08732695A	2020-12-11	Stada-Arzneimittel Aktiengesellschaft	Granted and Under Opposition
EP08732695A	2020-12-11	Gedeon Richter Plc.	Granted and Under Opposition
EP08732695A	2020-12-11	Kraus & Weisert Patentanwälte PartGmbB	Granted and Under Opposition
EP08732695A	2020-12-10	Zentiva, k.s.	Granted and Under Opposition
EP17203302A	2020-08-13	Generics (U.K.) Limited	Granted and Under Opposition
EP10782113A	2019-04-25	Hoefer & Partner Patentanwälte mbB	Granted and Under Opposition
EP15181545A	2018-09-06	Generics (U.K.) Limited	Granted and Under Opposition
EP10179007A	2017-03-22	Galenicum Health S.L.	Patent maintained as amended
EP05756474A	2017-01-20	Galenicum Health S.L.	Patent maintained as amended
EP07784499A	2015-04-30	LEK Pharmaceuticals d.d.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

USRE44186	June, 2016	FWD Entered	ASTRAZENECA AB	Aurobindo Pharma U.S.A., Inc.
USRE44186	June, 2016	FWD Entered	AstraZeneca AB	Amneal Pharmaceuticals LLC
USRE44186	June, 2016	FWD Entered	AstraZeneca AB	Teva Pharmaceuticals USA Inc.
USRE44186	May, 2016	FWD Entered	AstraZeneca AB	Wockhardt Bio AG
USRE44186	June, 2015	FWD Entered	AstraZeneca AB	Mylan Pharmaceuticals Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186	ASTRAZENECA AB	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	Jul, 2023 (a month ago)
US6515117	ASTRAZENECA AB	C-aryl glucoside SGLT2 inhibitors and method	Oct, 2025 (2 years from now)
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799	ASTRAZENECA AB	Coated tablet formulation and method	Jul, 2025 (1 year, 9 months from now)
US8501698	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Jun, 2027 (3 years from now)
US8716251	ASTRAZENECA AB	Pharmaceutical formulations containing an SGLT2 inhibitor	Mar, 2028 (4 years from now)
US9616028	ASTRAZENECA AB	Bilayer tablet formulations	Nov, 2030 (7 years from now)

Qternmet Xr is owned by Astrazeneca Ab.

Qternmet Xr contains Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride.

Qternmet Xr has a total of 7 drug patents out of which 1 drug patent has expired.

Expired drug patents of Qternmet Xr are:

Qternmet Xr was authorised for market use on 02 May, 2019.

Qternmet Xr is available in tablet, extended release;oral dosage forms.

Qternmet Xr can be used as treatment of type 2 diabetes mellitus.

The generics of Qternmet Xr are possible to be released after 12 November, 2030.

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	May 2, 2022

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM;EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
5MG;1GM;EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
5MG;1GM;EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
10MG;1GM;EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

QTERNMET XR family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic